Ann W Walsh
Overview
Explore the profile of Ann W Walsh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baldick C, Wichroski M, Pendri A, Walsh A, Fang J, Mazzucco C, et al.
PLoS Pathog
. 2010 Sep;
6(9):e1001086.
PMID: 20838466
Small molecule inhibitors of hepatitis C virus (HCV) are being developed to complement or replace treatments with pegylated interferons and ribavirin, which have poor response rates and significant side effects....
2.
Walsh A, Langley D, Colonno R, Tenney D
PLoS One
. 2010 Feb;
5(2):e9195.
PMID: 20169198
Background: Entecavir (ETV) is a deoxyguanosine analog competitive inhibitor of hepatitis B virus (HBV) polymerase that exhibits delayed chain termination of HBV DNA. A high barrier to entecavir-resistance (ETVr) is...
3.
Fang J, Wichroski M, Levine S, Baldick C, Mazzucco C, Walsh A, et al.
Antimicrob Agents Chemother
. 2009 May;
53(7):2762-72.
PMID: 19433559
Amino acid substitutions that confer reduced susceptibility to antivirals arise spontaneously through error-prone viral polymerases and are selected as a result of antiviral therapy. Resistance substitutions first emerge in a...
4.
Langley D, Walsh A, Baldick C, Eggers B, Rose R, Levine S, et al.
J Virol
. 2007 Feb;
81(8):3992-4001.
PMID: 17267485
Entecavir (ETV; Baraclude) is a novel deoxyguanosine analog with activity against hepatitis B virus (HBV). ETV differs from the other nucleoside/tide reverse transcriptase inhibitors approved for HBV therapy, lamivudine (LVD)...
5.
Tenney D, Rose R, Baldick C, Levine S, Pokornowski K, Walsh A, et al.
Antimicrob Agents Chemother
. 2006 Dec;
51(3):902-11.
PMID: 17178796
Entecavir (ETV) is a deoxyguanosine analog approved for use for the treatment of chronic infection with wild-type and lamivudine-resistant (LVDr) hepatitis B virus (HBV). In LVD-refractory patients, 1.0 mg ETV...